jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Article

Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‑label Study

Mrunalini Kalikar1★, Kundan S. Nivangune1, Ganesh N. Dakhale1, Chaitali S. Bajait1, Smita D. Sontakke1, Vijay M. Motghare1, Ritu Budania1★ Corresponding author

  1. 1Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.

CORRESPONDENCE

Mrunalini Kalikar

Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India.

mrunalinikalikar@yahoo.com

Received: 11-03-2017; Revised: 11-06-2017; Accepted: 10-07-2017.

Volume 8, Issue 3 · pp. 106–111 · PUBLISHED 2017 · DOI: 10.4103/jpp.JPP_39_17

View on JPP original site ↗

ABSTRACT

Objectives: To compare the efficacy and tolerability of losartan, telmisartan, and olmesartan as antihypertensive agents and evaluate and compare their effects on lipid profile and blood glucose. Materials and Methods: This was a randomized, open‑label, parallel‑group, comparative study conducted in sixty patients of Stage I hypertension. The eligible patients were randomly allocated into three treatment groups: (1) Tablet olmesartan (20 mg), (2) Tablet telmisartan (40 mg), and (3) Tablet losartan (50 mg). Blood pressure (BP) was assessed at an interval of 2 weeks for 3 months. Fasting blood glucose (FBG) and lipid profile were estimated at baseline and then at 12 weeks. Results: Olmesartan and telmisartan were more efficacious than losartan in reducing diastolic BP (DBP). There was a statistically significant decrease in mean blood glucose level (P < 0.02) after 12 weeks of treatment in telmisartan group when compared to baseline. Serum total cholesterol, triglycerides, and low‑density lipoproteins decreased significantly after 12‑week treatment with olmesartan and telmisartan. Conclusions: The most efficacious drug in reducing BP is Olmesartan whereas telmisartan and losartan show equal efficacy. Telmisartan shows the most favorable effects on FBG and lipid profile.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Kalikar, M., Nivangune, K. S., Dakhale, G. N., Bajait, C. S., Sontakke, S. D., Motghare, V. M., & Budania, R. (2017). Efficacy and Tolerability of Olmesartan, Telmisartan, and Losartan in Patients of Stage I Hypertension: A Randomized, Open‑label Study. Journal of Pharmacology and Pharmacotherapeutics, 8(3), 106–111. https://doi.org/10.4103/jpp.JPP_39_17